참고문헌
- NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy, March 7-29, 2000: highlights of the conference. South Med J 2001;94:569-573.
- Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis: the Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995;333:1437-1443. https://doi.org/10.1056/NEJM199511303332201
- Pols HA, Felsenberg D, Hanley DA, et al. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study: Fosamax International Trial Study Group. Osteoporos Int 1999;9:461-468. https://doi.org/10.1007/PL00004171
- Luf kin EG, Argueta R, Whitaker MD, et al. Pamidronate: an unrecognized problem in gastrointestinal tolerability. Osteoporos Int 1994;4:320-322. https://doi.org/10.1007/BF01622190
- Recker RR, Lewiecki EM, Miller PD, Reiffel J. Safety of bisphosphonates in the treatment of osteoporosis. Am J Med 2009;122(2 Suppl):S22-S32.
- Bauer DC, Black D, Ensrud K, et al. Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial. Arch Intern Med 2000;160:517-525. https://doi.org/10.1001/archinte.160.4.517
- Tucci JR, Tonino RP, Emkey RD, Peverly CA, Kher U, Santora AC 2nd. Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis. Am J Med 1996;101:488-501. https://doi.org/10.1016/S0002-9343(96)00282-3
- Lanza F, Rack MF, Simon TJ, Lombardi A, Reyes R, Suryawanshi S. Effects of alendronate on gastric and duodenal mucosa. Am J Gastroenterol 1998;93:753-757. https://doi.org/10.1111/j.1572-0241.1998.219_a.x
- de Groen PC, Lubbe DF, Hirsch LJ, et al. Esophagitis associated with the use of alendronate. N Engl J Med 1996;335:1016-1021. https://doi.org/10.1056/NEJM199610033351403
- Levine J, Nelson D. Esophageal stricture associated with alendronate therapy. Am J Med 1997;102:489-491. https://doi.org/10.1016/S0002-9343(97)89446-6
- Kelly R, Taggart H. Incidence of gastrointestinal side effects due to alendronate is high in clinical practice. BMJ 1997;315:1235.
- Ribeiro A, DeVault KR, Wolfe JT 3rd, Stark ME. Alendronate-associated esophagitis: endoscopic and pathologic features. Gastrointest Endosc 1998;47:525-528. https://doi.org/10.1016/S0016-5107(98)70256-1
- Ettinger B, Pressman A, Schein J. Clinic visits and hospital admissions for care of acid-related upper gastrointestinal disorders in women using alendronate for osteoporosis. Am J Manag Care 1998;4:1377-1382.
- Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, Naujoks C. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 2004;15:1003-1008. https://doi.org/10.1007/s00198-004-1652-z
- Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2006;81:1013-1022. https://doi.org/10.4065/81.8.1013
- Ezra A, Golomb G. Administration routes and delivery systems of bisphosphonates for the treatment of bone resorption. Adv Drug Deliv Rev 2000;42:175-195. https://doi.org/10.1016/S0169-409X(00)00061-2
- Shiraki M, Kushida K, Fukunaga M, et al. A doublemasked multicenter comparative study between alendronate and alfacalcidol in Japanese patients with osteoporosis: the Alendronate Phase III Osteoporosis Treatment Research Group. Osteoporos Int 1999;10:183-192. https://doi.org/10.1007/s001980050214
- Rhee Y, Kang M, Min Y, et al. Effects of a combined alendronate and calcitriol agent (Maxmarvil) on bone metabolism in Korean postmenopausal women: a multicenter, double-blind, randomized, placebo-controlled study. Osteoporos Int 2006;17:1801-1807. https://doi.org/10.1007/s00198-006-0200-4
- Genant HK, Wu CY, van Kuijk C, Nevitt MC. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 1993;8:1137-1148.
- Hetzel DJ, Dent J, Reed WD, et al. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology 1988;95:903-912.
- Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures: Fracture Intervention Trial Research Group. Lancet 1996;348:1535-1541. https://doi.org/10.1016/S0140-6736(96)07088-2
- Hosking D, Chilvers CE, Christiansen C, et al. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age: Early Postmenopausal Intervention Cohort Study Group. N Engl J Med 1998;338:485-492. https://doi.org/10.1056/NEJM199802193380801
- Maconi G, Bianchi Porro G. Multiple ulcerative esophagitis caused by alendronate. Am J Gastroenterol 1995;90:1889-1890.
- Graham DY, Malaty HM. Drug-induced gastric ulcers are caused by more than just NSAIDs: alendronate gastric ulcers. Gastroenterology 1998;114(Suppl 1):A138.
- Tosteson AN, Grove MR, Hammond CS, et al. Early discontinuation of treatment for osteoporosis. Am J Med 2003;115:209-216. https://doi.org/10.1016/S0002-9343(03)00362-0
- Shiraki M, Kushida K, Fukunaga M, et al. A placebocontrolled, single-blind study to determine the appropriate alendronate dosage in postmenopausal Japanese patients with osteoporosis: the Alendronate Research Group. Endocr J 1998;45:191-201. https://doi.org/10.1507/endocrj.45.191
- Haderslev KV, Tjellesen L, Sorensen HA, Staun M. Alendronate increases lumbar spine bone mineral density in patients with Crohn's disease. Gastroenterology 2000;119:639-646. https://doi.org/10.1053/gast.2000.16518
- Lowe CE, Depew WT, Vanner SJ, Paterson WG, Meddings JB. Upper gastrointestinal toxicity of alendronate. Am J Gastroenterol 2000;95:634-640. https://doi.org/10.1111/j.1572-0241.2000.01835.x
- Graham DY, Malaty HM. Alendronate and naproxen are synergistic for development of gastric ulcers. Arch Intern Med 2001;161:107-110. https://doi.org/10.1001/archinte.161.1.107
- Lanza F, Sahba B, Schwartz H, et al. The upper GI safety and tolerability of oral alendronate at a dose of 70 milligrams once weekly: a placebo-controlled endoscopy study. Am J Gastroenterol 2002;97:58-64. https://doi.org/10.1111/j.1572-0241.2002.05446.x
피인용 문헌
- Alendronate-induced unmasking or deterioration of coeliac disease: a case series vol.26, pp.1, 2013, https://doi.org/10.1007/s00198-014-2942-8
- Medication Use Patterns, Treatment Satisfaction, and Inadequate Control of Osteoporosis Study in the Asia-Pacific Region (MUSIC OS-AP): Design of a multinational, prospective, observational study exam vol.3, pp.None, 2013, https://doi.org/10.1016/j.bonr.2015.09.002
- Impact on Bisphosphonate Persistence and Compliance: Daily Postprandial Administration vol.26, pp.1, 2013, https://doi.org/10.11005/jbm.2019.26.1.39